iHope Network Members Include Illumina, GeneDx, Genome.One, and
HudsonAlpha; Dedicated to Help Find Answers for Underserved Families
with Children Facing Rare and Undiagnosed Diseases
SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2017--
Inc. (NASDAQ:ILMN) today announced the launch of the iHope Network,
a consortium of member institutions who have committed to providing
clinical whole genome sequencing (cWGS) to underserved families. Today,
the iHope Network consists of clinical laboratory members: Illumina,
Genome.One, GeneDx, HudsonAlpha and their affiliate healthcare partners.
Through whole-genome sequencing – the process of determining the genetic
code or instructions in the cells within a person’s body – the iHope
Network and their respective clinical partners strive to end years-long
diagnostic odysseys. These odysseys average seven years in length and
include multiple inconclusive tests, surgeries and procedures, many of
which do not result in answers or treatment options for these children
and their families.
The iHope Network members have committed to a minimum philanthropic
donation of 10 whole genome tests per year (10 patients). Additionally,
iHope Network organizations have agreed to donate the variants
identified through iHope to public databases, like Clinvar,
which are freely accessible, public archives of reports of the
relationships among human variations and their related symptoms or
diseases. By doing so, the public wealth of knowledge will continue to
grow and provide benefit to many more patients who depend on the
precision of genomic medicine.
With precision medicine and large-scale genomic initiatives being
launched across the globe, genomics is reaching an inflection point in
public awareness. The iHope program aims to build on that public
awareness by demonstrating how next-generation sequencing can create a
significant impact – by helping undiagnosed patients and their families
find long sought-after answers.
“We are delighted to become a participating partner of Illumina’s iHope
Network” said Jane Juusola, PhD, FACMG, Director of the Clinical
Genomics Program, GeneDx. “As a laboratory founded to address the needs
of patients diagnosed with rare genetic diseases, the very principle of
the iHope program aligns with our founding mission. Through our donation
of 10 whole-genome sequencing tests, we hope to bring closure to the
diagnostic odysseys for children with undiagnosed rare diseases.”
“We’ve seen firsthand how a diagnosis can help families get a clearer
understanding of the journey ahead,” said Marcel Dinger, CEO of
Genome.One, a wholly owned subsidiary of the Garvan Institute of Medical
Research. “We’re very pleased to be part of the iHope Network that will
help people who are currently unable to access clinical whole-genome
sequencing and help to raise awareness about the value of WGS for rare
and genetic disease.”
“The evidence is clear that genomic medicine can directly benefit
patients. And there are millions of patients who need whole-genome
sequencing today, and who cannot afford it,” said Howard J.
Jacob, Ph.D., Executive Vice President for Genomic Medicine and Chief
Genomic Medicine Officer, HudsonAlpha Institute for Biotechnology. “The
more people who are helped through this initiative, the better the
likelihood whole-genome sequencing will be integrated into clinical
practice around the globe. We are proud to join the iHope Network and
help save lives.”
The ultimate goal of the iHope Network is to increase awareness and
adoption of cWGS and demonstrate to the community that clinical whole
genomes are a needed resource for all pediatric patients facing rare and
undiagnosed diseases. An iHope Network Summit will take place later this
year. To learn more about the program or to become part of the iHope
Network, please visit: www.illumina.com/ihope.
GeneDx is a world leader in Genomics with an acknowledged expertise in
rare and ultra rare genetic disorders, as well as one of the broadest
menus of sequencing services available among commercial laboratories.
GeneDx provides testing to patients and their families in more than 55
countries. GeneDx is a business unit of BioReference Laboratories, a
wholly owned subsidiary of OPKO Health, Inc. To learn more, please visit www.genedx.com.
About Genome.One and the Garvan Institute of Medical Research
Genome.One (www.genome.one) is
a pioneering health information company providing genetic answers to
life’s biggest health questions through clinical Whole Genome
Sequencing. Genome.One aims to enhance the lives of patients, families
and communities across the world. Genome.One is a wholly owned
subsidiary of the Garvan Institute of Medical Research, Sydney,
Australia. Garvan’s mission is to make significant contributions to
medical science that will change the directions of science and medicine
and have major impacts on human health.
HudsonAlpha Institute for Biotechnology is a nonprofit institute
dedicated to innovating in the field of genomic technology and sciences
across a spectrum of biological challenges. Opened in 2008, its mission
is four-fold: sparking scientific discoveries that can impact human
health and well-being; bringing genomic medicine into clinical care;
fostering life sciences entrepreneurship and business growth; and
encouraging the creation of a genomics-literate workforce and society.
The HudsonAlpha biotechnology campus consists of 152 acres nestled
within Cummings Research Park, the nation’s second largest research
park. Designed to be a hothouse of biotech economic development,
HudsonAlpha’s state-of-the-art facilities co-locate nonprofit scientific
researchers with entrepreneurs and educators. The relationships formed
on the HudsonAlpha campus encourage collaborations that produce advances
in medicine and agriculture. Under the leadership of Dr. Richard M.
Myers, a key collaborator on the Human Genome Project, HudsonAlpha has
become a national and international leader in genetics and genomics
research and biotech education, and includes more than 30 diverse
biotech companies on campus. To learn more about HudsonAlpha, visit: http://hudsonalpha.org/.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and
View source version on businesswire.com: http://www.businesswire.com/news/home/20170228005630/en/
Source: Illumina, Inc.